Fibromyalgia: History and Discovery

Fibromyalgia — chronic widespread pain accompanied by fatigue, unrefreshing sleep, and bodily tenderness — has been recognized for far longer than it has been understood. Physicians described its picture of aching, stiffness, and tender spots throughout the 1800s, but the name it carried for most of the twentieth century, fibrositis, rested on a mistake: it implied an inflammation that careful investigation never found. The journey from that misnomer to the modern concept of central sensitization — a nervous system that amplifies pain — is also a story about people, mostly women, who were told for generations that their suffering was imaginary. This page traces how the condition was named, doubted, redefined, and at last taken seriously, and it tries to do so with the respect that history owes them.

Table of Contents

  1. What Fibromyalgia Is
  2. Early Descriptions: Muscular Rheumatism and Tender Points
  3. 1904: Gowers Coins “Fibrositis” — a Misnomer
  4. The 1970s: Sleep, Tender Points, and a New Foundation
  5. 1976–1981: From Fibrositis to Fibromyalgia
  6. 1990 and Beyond: The ACR Classification Criteria
  7. Central Sensitization: The Modern Understanding
  8. “All in Your Head”: A Harmful History
  9. Fibromyalgia Today
  10. Research Papers and References
  11. Connections

What Fibromyalgia Is

Fibromyalgia is a long-term condition defined by chronic widespread pain — pain on both sides of the body, above and below the waist, lasting at least three months — together with persistent fatigue, sleep that does not refresh, and a heightened sensitivity to pressure and other stimuli. Many people also experience “fibro fog” (difficulty with memory and concentration), headaches, irritable bowel symptoms, and mood disturbance. Crucially, the joints are not damaged and the muscles are not visibly inflamed; the problem lies in how pain itself is processed.

That last point is what makes the history of fibromyalgia so distinctive. For most conditions, doctors first find a lesion — a broken bone, an inflamed joint, a tumor — and then name it. Fibromyalgia had no visible lesion to find, which is exactly why it was misnamed for seven decades and why patients were so often disbelieved. Understanding the condition required a shift away from looking for damage in the tissues and toward understanding the nervous system as the source of amplified pain. The sections below follow that long shift, from the first nineteenth-century observers of “muscular rheumatism” to today’s model of central sensitization.

Back to Table of Contents

Early Descriptions: Muscular Rheumatism and Tender Points

The cluster of symptoms we now call fibromyalgia was described in the medical literature throughout the nineteenth century, long before any modern name existed. Physicians of the era grouped such complaints under the broad heading of muscular rheumatism — a term for painful, stiff, aching conditions of the soft tissues that, unlike gout or what we now call rheumatoid arthritis, did not deform the joints or change the body’s structure. Within that loose category, careful clinicians repeatedly noticed something specific: certain spots on the body were unusually tender to pressure.

The Scottish surgeon William Balfour is often credited as an early observer; in the 1810s he described tender, nodular points in the muscles and connected them to this kind of rheumatic pain. A few decades later the French physician François Valleix, in his 1841 Traité des Névralgies (Treatise on Neuralgia), wrote at length about points of tenderness, and the German physician Robert Froriep reported, in 1843, areas of hardness or “callosities” that could be felt in the muscles of rheumatic patients. These authors are named here as historical sources rather than as modern citations; the detailed bibliography is traced in the standard review by Inanici and Yunus listed below.

What unites these scattered early reports is a recurring observation — widespread aching with discrete tender spots and no joint deformity — described independently by different clinicians in different countries. They had no agreed name for it and no explanation, but they had clearly seen the same thing. That accumulating record set the stage for the term that would dominate, and distort, the twentieth-century understanding of the condition.

Back to Table of Contents

1904: Gowers Coins “Fibrositis” — a Misnomer

In 1904, the eminent British neurologist Sir William Richard Gowers proposed a new name for this painful condition of the muscles and fibrous tissues. In a lecture published in the British Medical Journal — titled “Lumbago: Its Lessons and Analogues” — Gowers suggested calling the disorder fibrositis, built from the Latin for fiber (fibro-) plus the medical suffix -itis, meaning inflammation. He believed the pain arose from inflammation of the fibrous tissue within and around the muscles.

The name was influential and it stuck — but it was wrong. The suffix -itis is a strong claim: it asserts that inflammation is present. When pathologists later examined the painful tissues of these patients, they did not find the inflammation that the word promised. There was no consistent swelling, no infiltration of inflammatory cells, none of the hallmarks that justify an -itis. Gowers had named a real condition but attributed it to the wrong mechanism, and the medical world inherited a term that actively misdescribed the disease for the next seventy-two years.

This is more than a footnote about etymology. Because “fibrositis” promised an inflammation that could never be demonstrated, the diagnosis grew an air of unreliability. A label that points to a lesion no one can find invites the suspicion that there is no real disease at all — a suspicion that, as later sections describe, fell heavily and unfairly on the patients who carried the diagnosis. Correcting the misnomer would take most of the century and a fundamentally different idea of where the pain came from.

Back to Table of Contents

The 1970s: Sleep, Tender Points, and a New Foundation

The modern scientific story of fibromyalgia begins in the 1970s, centered on the work of two Canadian researchers at the University of Toronto: the rheumatologist Hugh Smythe and the sleep researcher Harvey Moldofsky. Smythe is frequently described as a father of modern fibromyalgia for his early 1970s work pulling the scattered clinical picture together — widespread pain plus characteristic tender points at specific, reproducible body sites — into a coherent syndrome that could actually be studied.

The other pillar was sleep. Patients with this condition almost universally reported that their sleep left them unrefreshed, waking tired and sore. In a landmark sleep-laboratory study published in 1975, Moldofsky and Smythe recorded the brain-wave (electroencephalogram, or EEG) patterns of patients and found an abnormal intrusion of fast, waking-type “alpha” brain waves into the deep, slow-wave sleep that is normally most restorative — the so-called alpha–delta sleep anomaly. Strikingly, when healthy volunteers were deliberately deprived of that deep sleep, they began to develop musculoskeletal aching and tenderness resembling the patients’ symptoms.

This work mattered for two reasons. First, it offered the first objective, measurable abnormality associated with the condition — something a machine could record, not merely something a patient reported. Second, it reframed the problem: the disorder was not in inflamed fibers but somewhere in the nervous system, in the very regulation of sleep and pain. In 1977, Smythe and Moldofsky published proposed diagnostic criteria built around their core features — widespread pain, multiple tender points, unrefreshing sleep, and fatigue — giving clinicians, for the first time, a practical way to identify the syndrome consistently.

Back to Table of Contents

1976–1981: From Fibrositis to Fibromyalgia

With inflammation ruled out and the nervous system implicated, the inherited name had become indefensible. Around 1976, the term fibromyalgia came into use as a replacement for fibrositis — the new word built from fibro- (fibrous tissue), the Greek my- (muscle), and -algia (pain). It is usually attributed to the rheumatologist P. K. Hench, who is credited with using “fibromyalgia” in this period to describe non-articular rheumatism. The change was deliberate and honest: -algia simply means pain, making no false claim of inflammation. The name describes what is actually there — pain in the muscles and fibrous tissues — and nothing that isn’t.

The new name needed scientific substance, and it was provided in 1981 by Muhammad B. Yunus and colleagues. Their paper, “Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls,” published in Seminars in Arthritis and Rheumatism, was the first controlled study of the syndrome: it compared fifty patients against fifty matched healthy controls and, by doing so, supplied the first data-driven diagnostic criteria. The study confirmed the core features — widespread pain, a high count of tender points, fatigue, poor sleep — and documented the now-familiar associations with irritable bowel symptoms and headaches. Yunus is widely regarded as the author who established fibromyalgia as a definable clinical entity on a scientific footing.

Within roughly five years, then, the condition was transformed: it shed a misleading name it had carried since 1904, acquired an accurate one, and gained its first rigorous, controlled evidence base. The transitional phrasing “fibromyalgia (fibrositis)” seen in titles of the era reflects exactly this handover — the old term kept briefly in parentheses so readers would know that the new word named the same long-recognized disorder.

Back to Table of Contents

1990 and Beyond: The ACR Classification Criteria

For research to advance, scientists studying fibromyalgia in different cities needed confidence they were studying the same patients. That standardization arrived in 1990, when a multicenter committee of the American College of Rheumatology (ACR), in a report led by Frederick Wolfe, published the first widely adopted classification criteria. The 1990 criteria required two things: a history of widespread pain present for at least three months, and pain on firm finger pressure at at least 11 of 18 designated tender-point sites distributed around the body. This combination identified fibromyalgia with roughly 88% sensitivity and 81% specificity, and for the first time gave the field a common, testable definition.

The tender-point examination, however, proved awkward in practice. It was time-consuming, the pressure was hard to standardize between examiners, many physicians never learned to perform it reliably, and it captured only one dimension of an illness that also involves profound fatigue, unrefreshing sleep, and cognitive difficulty. Recognizing these limits, the ACR issued revised 2010 diagnostic criteria (with a 2011 self-report modification for research) that dropped the tender-point exam entirely. In its place came two questionnaire-based scores: a Widespread Pain Index counting the number of painful body regions, and a Symptom Severity scale rating fatigue, waking unrefreshed, and cognitive symptoms. A further 2016 revision refined these rules — combining the physician and questionnaire approaches, reducing the misclassification of purely regional pain, and clarifying that fibromyalgia could coexist with other diagnoses rather than being excluded by them.

The arc of these criteria mirrors the deepening understanding of the disease. The 1990 standard still looked for the answer at specific tender spots on the body; the 2010 and 2016 standards accept that fibromyalgia is a systemic, symptom-based condition whose essence is widespread pain plus fatigue, sleep, and cognitive disturbance — a picture pointing squarely at the central nervous system.

Back to Table of Contents

Central Sensitization: The Modern Understanding

The central concept in modern fibromyalgia science is central sensitization: a state in which the central nervous system — the brain and spinal cord — amplifies pain signals, so that ordinary sensations are felt as painful and genuinely painful stimuli are felt as far worse. A common and useful analogy describes it as the body’s “volume control” for pain being turned up too high. The wiring is intact; the gain is wrong.

Two clinical phenomena express this amplified state. Allodynia is pain from things that should not hurt at all — a light touch, the seam of a shirt, a gentle hug. Hyperalgesia is an exaggerated response to things that are mildly painful, so that a small pressure produces large pain. Research into the pain pathways suggests that both the ascending pathways (carrying signals up to the brain) and the descending pathways (which normally dampen pain) function abnormally in fibromyalgia, tilting the whole system toward amplification. Neuroimaging and studies of pain-signaling chemicals have lent support to this model, and it helps explain a frustrating clinical fact: because the trouble is in central pain processing rather than in damaged tissue, treatments aimed at the periphery — anti-inflammatory drugs, opioids, injections, surgery — tend to work poorly, while approaches that act on the nervous system are often more useful.

It is fair and important to note that fibromyalgia remains an area of active research, and not every detail is settled. Scientists continue to investigate contributions from the peripheral nerves and the small nerve fibers of the skin, from genetics, from physical or emotional trauma and infection as triggers, and from the immune system. The unifying idea — that fibromyalgia is fundamentally a disorder of pain regulation and central sensitization rather than of inflamed or damaged tissue — is the best-supported framework available, and it is the one that finally makes sense of a century of puzzling observations. Where specific mechanisms are still being worked out, this page treats them as ongoing hypotheses rather than settled fact.

Back to Table of Contents

“All in Your Head”: A Harmful History

No honest history of fibromyalgia can omit the way patients were treated along the way. Because the condition showed no inflammation, no joint damage, and no abnormality on routine blood tests or X-rays, and because it affects women far more often than men, generations of patients — the great majority of them women — were told their pain was imaginary: psychosomatic, exaggerated, or simply “all in your head.” The historical record includes physicians dismissing sufferers as nervous or as “worry warts,” and proposals that the disorder be relabeled “psychogenic rheumatism.” This was not a fringe attitude; it was, for decades, a mainstream medical reflex when a complaint could not be matched to a visible lesion.

The human cost of that disbelief was real. Patients endured years of delayed diagnosis, were passed from specialist to specialist, were prescribed inappropriate treatments or none at all, and — perhaps worst of all — absorbed the message that they could not trust their own bodies. The dismissal also carried a clear gender dimension: women’s pain has historically been more readily attributed to emotion than to disease, and fibromyalgia sat squarely in the path of that bias. To anyone who lived through it, the demand to “prove” an invisible illness was exhausting and demoralizing.

The science described above is, in part, the answer to that disbelief. Objective findings — the disrupted deep sleep recorded in the 1970s, the reproducible tender points, and later the neuroimaging and pain-chemistry evidence of central sensitization — gradually established that fibromyalgia has a measurable biological basis. A firm diagnosis today does more than label a problem: it validates a reality that patients were long denied. This page is written in that spirit. Fibromyalgia is real, the pain is real, and the people who carried it through decades of doubt deserved to be believed far sooner than they were.

Back to Table of Contents

Fibromyalgia Today

Fibromyalgia is now a recognized condition managed chiefly within rheumatology and pain medicine, the two specialties best equipped to address widespread musculoskeletal pain and disordered pain processing. It is understood as common, affecting a meaningful share of the adult population, and as a legitimate diagnosis rather than a diagnosis of exclusion or a synonym for malingering. Management today is multimodal — combining education, graded exercise and movement, attention to sleep, psychological strategies such as cognitive behavioral therapy, and centrally-acting medications — reflecting the recognition that the problem lives in the nervous system’s handling of pain.

The condition also sits within a wider family of central sensitivity syndromes — overlapping conditions, including chronic fatigue syndrome (myalgic encephalomyelitis), irritable bowel syndrome, and chronic migraine, that share features of amplified central pain and sensory processing. A great deal of the modern framework for thinking about these overlapping illnesses traces back to the fibromyalgia research of Yunus and others, who argued that they belong together as disorders of central sensitization rather than as unrelated curiosities.

The history of fibromyalgia is ultimately a story of correction: a real disease named for the wrong reason in 1904, mistrusted for most of a century, and at last understood as a disorder of how the nervous system processes pain. The path from fibrositis to fibromyalgia, and from “all in your head” to central sensitization, is a reminder that the absence of a visible lesion is not the absence of disease — and that medicine’s willingness to keep looking, and to believe patients while it does, is what eventually turns mystery into knowledge.

Back to Table of Contents

Research Papers and References

The references below combine landmark peer-reviewed papers in the history and science of fibromyalgia with curated PubMed topic-search links into the wider literature. Historical primary texts — Gowers’ 1904 British Medical Journal lecture, Valleix’s 1841 Traité des Névralgies, and the nineteenth-century reports of Balfour and Froriep — are named in the article as historical sources rather than as modern citations. Each link opens at its source (National Library of Medicine / publisher) in a new tab.

  1. Inanici F, Yunus MB. History of fibromyalgia: past to present. Current Pain and Headache Reports. 2004;8(5):369-378. — doi:10.1007/s11916-996-0010-6 (PMID: 15361321)
  2. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism. 1981;11(1):151-171. — PMID: 6944796
  3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis & Rheumatism. 1990;33(2):160-172. — doi:10.1002/art.1780330203 (PMID: 2306288)
  4. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research. 2010;62(5):600-610. — doi:10.1002/acr.20140
  5. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism. 2016;46(3):319-329. — doi:10.1016/j.semarthrit.2016.08.012
  6. Smythe HA, Moldofsky H. Two contributions to understanding of the “fibrositis” syndrome. Bulletin on the Rheumatic Diseases. 1977-78;28(1):928-931. — PMID: 199304
  7. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555. — doi:10.1001/jama.2014.3266
  8. Sir William Gowers and the term “fibrositis” (1904) — historical context — PubMed: Gowers, fibrositis, and the history of fibromyalgia
  9. Central sensitization in fibromyalgia — mechanisms and evidence — PubMed: fibromyalgia and central sensitization
  10. Moldofsky and the sleep (alpha–delta) anomaly in fibromyalgia — PubMed: Moldofsky, sleep EEG, and fibromyalgia
  11. Evolution of the fibrositis/fibromyalgia tender-point concept — PubMed: tender points and the fibrositis/fibromyalgia concept
  12. Central sensitivity syndromes and the overlap of fibromyalgia with related conditions — PubMed: central sensitivity syndromes (Yunus)
  13. Stigma, gender, and the dismissal of fibromyalgia as “psychogenic” — PubMed: fibromyalgia, stigma, and legitimacy

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents